GlassScriptPhysician profile
Brian G Williams
NPI 1598701914
$2,853.92
in general payments reported to CMS, 2019-2025
27 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.48 · 2023: $1,536 · 2024: $1,075 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.44 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.83 | 2023-2024 | |
| Lilly USA, LLC | $365.71 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $274.37 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $235.11 | 2023-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $202.40 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $167.01 | 2023-2024 | Auvelity |
| Novo Nordisk INC | $159.07 | 2023-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $130.41 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.30 | 2023 | |
| Amgen INC. | $114.18 | 2023-2025 | Repatha, Otezla, Otezla |
| Halozyme INC | $96.68 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.23 | 2023-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.54 | 2023-2024 | Jardiance |
| Shield Therapeutics INC | $52.45 | 2023-2024 | Accrufer |
| Ardelyx, INC. | $48.43 | 2023-2024 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $36.48 | 2021 | Xyosted |
| Glaxosmithkline, LLC. | $29.92 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $24.04 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Daiichi Sankyo INC. | $22.96 | 2024 | Injectafer |
| Lundbeck LLC | $22.35 | 2023 | Vyepti |
| Mylan Specialty L.P. | $21.70 | 2023 | Yupelri |
| Baxter Healthcare | $20.34 | 2024 | Hillrom - Monarch Airway Clearance System |
| Esperion Therapeutics, INC. | $18.94 | 2023 | Nexletol |
| Exact Sciences Corporation | $17.71 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $16.34 | 2023 | Quviviq |
| Dexcom, INC. | $16.21 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $8.21 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.